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The erythroid differentiation-inducing effect of apigenin and its derivatives on human chronic myeloid
leukemia K562 has been reported but the functional group in its structure responsible for the effect
has not yet been elucidated. Here, we determined the moiety responsible for the erythroid differentiation
induction effect of apigenin by using different ﬂavonoids to represent the functional groups in its struc-
ture. In addition, we compared apigenin and apigetrin, a ﬂavonoid similar in structure to apigenin except
for the glycoside in its structure. Morphological changes as well as expressions of speciﬁc markers in
K562 cells treated with apigenin were compared with those treated with apigetrin, ﬂavone, 7-hydroxyf-
lavone, chrysin, luteolin, or naringenin. The anti-proliferative and erythroid differentiation-inducing
effect of apigenin and the ﬁve ﬂavonoids were then investigated and their effects on the a, b, and c globin
genes expressions were compared using real-time PCR. Results of the comparison between apigenin and
apigetrin revealed that the glycoside part of apigetrin does not have a role in the induction of cell
differentiation. Based on glycophorin A expression, the potency of the other ﬂavonoids for induction of
differentiation, was: apigenin > chrysin > ﬂavone/7-hydroxyﬂavone > luteolin/naringenin. Results of the
analysis of the relationship between the structure and function of the ﬂavonoids suggest that the
apigenin-induced K562 cell differentiation was due to the 2–3 double bond and hydroxyl groups in its
structure. This is the ﬁrst study that identiﬁed the speciﬁc functional group in apigenin that impact
the erythroid differentiation effect in K562 cells.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Plant bioactive compounds have great potential role in the pre-
vention or cure of diseases. Recently, the beneﬁcial effects of phy-
tochemicals from fruits, vegetables, grains and herbal medicine on
human health has gained a major interest [1]. At present, more
than 8000 different polyphenolic compounds are known, the most
abundant phytochemicals are ﬂavonoids constituting of more than
4000 compounds [2]. Flavonoids have various beneﬁts for human
health due to its anti-oxidant and free-radical scavenger activities
as well as anti-inﬂammatory, antiviral, and anti-cancer properties
[3,4]. The ﬂavonoid’s structure consists of two aromatic rings (ring
A and ring B) linked by three carbons representing the C ring. Vari-
ations in the heterocycle (ring C) deﬁne the different subclasses ofﬂavonoids. The compounds in each subclass are deﬁned by their
hydroxylation and conjugation patterns. Flavonoids are frequently
found in nature in the glycosylated or esteriﬁed forms [5].
Apigenin is recognized as a bioactive ﬂavonoid shown to pos-
sess anti-inﬂammatory, antioxidant. The inhibitory effect of apige-
nin against UVB-induced cyclooxygenase-2 (COX-2) expression in
keratinocyte [6], TNFa-induced NF-kB transcription activation,
and chemokine expressions [7] have been reported. In addition,
apigenin also inhibits whole body gamma (c)-irradiation, oxidative
damage and hematological alterations in Swiss albino mice. [8].
Apigenin has also been shown to possess growth inhibitory prop-
erties in several cancer lines, including breast, colon, skin, thyroid,
and leukemia cells [9–13]. In our previous study, we provided
additional evidence to the fact that ﬂavonoids are potent inducers
of leukemia cell differentiation and demonstrated that the ﬂavo-
noid apigenin-7-glycoside (Fig. 1) can induce acute myeloid leuke-
mia HL-60 cells and chronic myeloid leukemia K562 cells to
differentiate to the granulocytic and the erythrocytic lineages,
respectively [14,15]. The characteristic feature of hematological
Fig. 1. Chemical structures of apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-
benzopyran-4-one) and apigetrin (5-hydroxy-2-(4-hydroxyphenyl)-7-
[(2S,3R,4S,5S,6R)-3,4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-
one).
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particular stage in its maturation. During the past three decades,
a new concept of treating leukemia that forces the malignant cells
to undergo terminal differentiation instead of induction of cell
death, referred to as ‘‘differentiation therapy’’ has been developed
[16]. Although studies on the relationship between the chemical
structure of ﬂavonoids and their anti-leukemia effect have already
been reported, most of these studies were on the ﬂavonoids’ anti-
proliferative and the apoptosis-inducing activities [17,18]. It has
been established that the effectiveness of ﬂavonoids as therapeu-
tics is dependent on their speciﬁc structural characteristics
[13,19,20]. Here, we characterized the differentiation–induction
effect of apigenin (Fig. 1) on K562 cells and revealed which func-
tional group in its chemical structure is responsible for anti prolif-
erative effect and/or including cell arrest.
2. Materials and methods
2.1. Cell line and culture conditions
Human chronic leukemia cell line K562 was obtained from the
Riken cell bank (Tsukuba, Ibaraki, Japan). Cells were cultured in
RPMI 1640 medium (Gibco), supplemented with 10% heat-inacti-
vated fetal bovine serum and maintained at 37 C in a humidiﬁed
incubator with 5% CO2. The cells were pass-cultured every 3 days
and used for experiments after reaching the exponential growth
phase.
2.2. Chemicals used for cell treatment
Apigenin, apigetrin, and naringenin were purchased from Sigma
Aldrich (St. Louis, MO), luteolin from Wako Pure Chemical Indus-
tries, Ltd. of Japan while ﬂavone and 7-hydroxyﬂavone were
obtained from Tokyo Chemical Industry Co., Ltd of Japan. Each
sample was dissolved in dimethylsulfoxide (DMSO) (Wako, Japan)
and stored at 20 C. Treatment of cells was carried out by diluting
the stock solution in culture medium immediately before use.
Cytosine arabinoside (Ara-C) at 25 lMwas used as positive control
for erythrocyte differentiation.
2.3. MTT assay
The effect of apigenin, apigetrin, ﬂavone, 7-hydroxyﬂavone,
chrysin, luteolin or naringenin (25, 50, or 100 lM) on the prolifer-
ation of K562 cells was investigated using the MTT [3-(4,5-Dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. K562 cells
were seeded into 96-well plates at 2  103 cells per well. After
incubation for 24 h, the ﬂavonoids were added at a ﬁnal concentra-
tion of 50 lM. Control cells were treated with DMSO (0.1%). MTT
was added after 72 h of incubation and the resulting formazan
was completely dissolved in 100 lL of 10% sodium dodecyl
sulfate (SDS). The absorbance was determined at 570 nm in amultidetection microplate reader (Power-scan HT, Dainippon
Pharmaceutical, NJ, USA).
2.4. Cell viability assay and cell morphological changes
The viability of K562 cells treated with of apigenin, apigetrin,
ﬂavone, 7-hydroxyﬂavone, chrysin, luteolin, or naringenin was
measured using Countess automatic cell counter (Invitrogen,
Carlsbad, CA). Brieﬂy, cells were seeded into 100-mm culture
dishes at 2  104 cells/mL and treated with 50 lM of each ﬂavo-
noid for the indicated incubation times. After collecting and stain-
ing the cells with trypan blue, of the viable and non-viable cell
counts were calculated using Countess Automated Cell Counter
(Invitrogen). Morphological changes were observed using a phase
contrast microscope (Leica Microsystems, Wetzlar, Germany).
2.5. Glycophorin A expression assay
The determination of which part of the apigenin structure
imparts the erythroid differentiation effect was assessed by mea-
suring the expression of glycophorin A, using a ﬂow cytometer
(Guava Technologies, Inc.), on the surface of K562 cells treated with
representative ﬂavonoids apigetrin, ﬂavone, 7-hydroxyﬂavone,
chrysin, luteolin or naringenin. Cells were seeded at 2  104 cells/
mL in 100-mm culture dishes and incubated for 24 h at 37 C in a
humidiﬁed 5% CO2 incubator prior to treatmentwith each ﬂavonoid
(at 50 lM concentration). Cells were then incubated for 3–6 days,
changing the medium after 3 days of incubation. Cells were then
harvested and the cell count adjusted to 1  105 cells/mL. After
washing with PBS, cells were labeled with PE-conjugated anti-
glycophorin A for 30 min according to manufacturer’s instructions.
Cells were washed twice with PBS and resuspended in 500 lL PBS
prior to measurement of glycophorin A expression.
2.6. Expressions of a-globin, b-globin and c-globin mRNA
Quantitative real-time PCR using speciﬁc primers for a-globin,
b-globin or c-globin was carried out to evaluate the expressions
of a-globin, b-globin and c-globin in K562 cells treated with or
without apigenin, apigetrin, ﬂavone, 7-hydroxyﬂavone, chrysin,
luteolin, or naringenin. After seeding 2  104 K562 cells/mL in
100-mm cell culture dishes and incubating them for 24 h, each
compound was added to a ﬁnal concentration of 50 lM. DNA-free
total RNA was isolated using Isogen (Nippongene, Tokyo, Japan)
following the manufacturer’s instructions. Isolated RNA was quan-
tiﬁed using a Nanodrop 2000 (Themo Scientiﬁc, Wilmington, DE)
and 1 lg of which was used as a template for cDNA synthesis done
using a thermal cycler (Applied Biosystems). Real-time PCR was
performed on the Applied Biosystems 7500 Real-Time PCR System,
using TaqMan probe-based detection (Applied Biosystems). The
Assay ID of the primers (Applied Biosystems) used for RT-PCR are
the following: Hs00361191_g1 for Alpha-Globin, Hs00758889_s1
for Beta-Globin, Hs00361131_g1 for Gamma-Globin. The expres-
sions of the globins’ mRNA were determined and normalized to
the internal control (b-actin) mRNA levels.
2.7. Statistical analysis
The differences between the means of the effect of the samples
on hemoglobin genes’ expressions were analyzed using js-STAR
2012 Software and Bonferroni multiple comparison tests [21]. In
other assays, the mean value ± SD and the differences between
treated and control treatments were evaluated for signiﬁcance
using the Student’s t-test. Differences between the means at the
5% conﬁdence level were considered signiﬁcant.
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3.1. Effect of glucose moiety on induction erythroid differentiation
(apigenin vs apigetrin)
The expression of glycophorin A in K562 cells, treated with dif-
ferent concentrations of apigenin, was assessed. Results showed
that 50 lMapigenin had the highest differentiation induction effect
at 31.6% after 6 days of treatment (Fig. 2a). To conﬁrm the erythroid
differentiation of K562 cells, the expression levels of a-, b-, and
c-hemoglobin genes, especially the a- and c-hemoglobins, were
increased by treatmentwith apigetrin, in a time-dependentmanner
(Fig. 2b).
The erythroid differentiation induction effect of apigenin and
apigetrin was then compared to investigate the role of the sugar
moiety present in apigetrin but not in apigenin. Cells treated with
50 lM apigenin or 75 lM apigetrin for 3 days had similar morphol-
ogy and appeared to be bigger in size compared to the control or
untreated cells (Fig. 3a). Results of the differentiation assay
revealed that cells treated with apigenin or apigetrin expressed
about the same level of glycophorin A at 17.5% and 16.4%,(a) 
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Fig. 2. Erythroid differentiation effect of apigenin on K562 cells. (a) Expression of
glycophorin A in K562 cells treated with 25, 50, 75, or 100 lM of apigenin for 6 days
assessed using Guava Express software. (b) Relative hemoglobin gene expression in
apigenin-treated cells treated with 50 lM of apigenin for 2, 4, 6 or 8 days of
incubation. The expressions of genes (every two days) speciﬁc to erythrocytes (a, b,
and c hemoglobin) were quantiﬁed using real-time PCR. The mRNA levels of the
hemoglobins were normalized to the internal control (b-actin). Differences between
means and signiﬁcance of the treatments were analyzed using js-STAR 2012
software and Bonferroni multiple comparison tests. ⁄P < 0.5% compared with a-
hemoglobin expression in apigenin-treated cells for 2 days; #P < 0.5% compared
with b-hemoglobin expression in apigenin-treated cells for 2 days; §P<0.5%
compared with c-hemoglobin expression in apigenin-treated cells for 2 days. Data
represent the means ± SD (n = 3).respectively (Fig. 3b). These results were corroborated by the levels
of a, b, and c hemoglobin mRNA expressions in cells treated with
apigenin or apigetrin. In addition, the quantity of globin mRNA in
K562 cells, treated with 50 lM apigenin or 75 lM apigetrin was
the same (Fig. 3c). These results establish that the glycoside moeity
in the structure of apigetrin is not involved in the induction of
erythroid differentiation.
3.2. Anti-proliferative effect of apigenin on K562 cells
Five ﬂavonoids that are structural analogs to the functional
groups in the apigenin structure were chosen to represent the
functional groups in the apigenin structure to investigate which
moiety is responsible for the erythroid differentiation effect
(Fig. 4). These ﬂavonoids (apigenin, ﬂavone, 7-hydroxyﬂavone,
chrysin, luteolin and naringenin) differ in the number and position
of hydroxyl group in their ﬂavonoid backbone. To evaluate the
effect of these ﬂavonoids on cell proliferation, K562 cells treated
with 25, 50, or 100 lM of the ﬂavonoids, incubated for 72 h, and
subjected to MTT assay. Results showed that all the ﬂavonoids,
except naringenin, decreased the proliferation of K562 cells in a
dose-dependent manner (Fig. 5a). Moreover, the anti-proliferative
effect of apigenin, ﬂavone and luteolin was greater than those of
chrysin and 7-hydroxyﬂavone. To ﬁnd out if the anti-proliferative
effect of apigenin was an indication of cell death or growth inhibi-
tion, we counted K562 cells following treatment with the different
ﬂavonoids using trypan blue exclusion method. K562 cells treated
with apigenin, ﬂavone, 7-hydroxyﬂavone, chrysin, or luteolin at
different treatment concentrations were signiﬁcantly less than
the control (untreated), while the number of naringenin-treated
cells remained the same as the control cells (data not shown).
The number of K562 cells when treated with apigenin, ﬂavone
and luteolin was less than the 7-hydroxyﬂavone- and chrysin-trea-
ted cells. However, although the number of cells were lower com-
pared to the untreated cells, the viability of cells treated with the
different ﬂavonoids, at all the treatment concentrations, remained
P80% except for those treated with 100 lM apigenin, ﬂavone or
luteolin, or cells treated with 50 lM luteolin (Fig. 5b), suggesting
the occurrence of cell cycle arrest. These results conﬁrmed previ-
ous reports that apigenin, ﬂavone, 7-hydroxyﬂavone and chrysin
at 50 lM concentration has an anti-proliferative effect on K562
by arresting cell growth. Changes in the morphology of K562 cells,
characterized by an increase in cell size, were also observed follow-
ing treatment with the different ﬂavonoids especially in cells trea-
ted with apigenin, ﬂavone, chrysin or luteolin. No remarkable
changes were observed in the naringenin- or 7-hydroxyﬂavone-
treated cells (Fig. 6). The morphological changes observed correlate
with the compounds’ cell differentiation effects based on the gly-
cophorin A assay (Fig. 7).
3.3. Glycophorin A expression in K562 cells
Ara-C was used as a positive control for erythroid differentia-
tion and increase in cell size and cessation of cell proliferation
has been observed in Ara-C- and c-irradiation-treated K562 cells
that underwent erythroid differentiation [22]. Here, microscopic
observations also showed morphological changes in K562 cells
treated with Ara-C or apigenin, and these morphological changes
were observed alongside erythroid differentiation, to evaluate the
ability of the ﬂavonoids to induce erythroid differentiation in
K562 cells, the expression of glycophorin A, a speciﬁc erythrocyte
marker, was determined by ﬂow cytometry. K562 cells were trea-
ted with 50 lM of each ﬂavonoid or Ara-C, and incubated for
5 days. Signiﬁcant erythroid differentiation effect was caused
by apigenin (31.04 ± 6.4%), chrysin (27.7 ± 3.7%), ﬂavone
(18.3 ± 3.4%) and 7-hydroxyﬂavone (19.5 ± 2.9%). Luteolin and
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Fig. 3. Erythroid differentiation induction effect of apigenin vs apigetrin. (a) Morphological changes in apigenin- and apigetrin-treated K562 cells. Scale bars represent 10 lm.
(b) Expression of glycophorin A on the cell surface of apigenin- and apigetrin-treated cells analyzed by ﬂow cytometrically using the Guava Express software. (c) Relative
expressions of a, b and c hemoglobin genes in K562 cells treated for 3 days with 50 lM and 75 lM of apigenin and apigetrin were analyzed using real-time PCR. Hemoglobin
mRNA levels were normalized to the mRNA levels of the internal control (b-actin). Results represent the mean mRNA expression level of the genes. ⁄ Statistically signiﬁcant
(P < 0.05) means difference between the control and treated cells for a and c hemoglobin genes, respectively. Data represent the means ± SD (n = 3).
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that were not signiﬁcantly different from the control cells
(10.4 ± 4.0 and 7.1 ± 1.7%, respectively) (Fig. 7).3.4. Apigenin-induced expressions of a, b, and c globin genes
Erythroid differentiation is accompanied by the synthesis of
hemoglobin proteins that characterize erythrocytes. To validate
the erythroid differentiation induction effects of the ﬂavonoids,
the expressions of a-hemoglobin, b-hemoglobin and c-hemoglobin
mRNA in K562 cells were quantiﬁed. Results showed that com-
pared to the control, a and c hemoglobin mRNA expressions were
increased by 9.3-fold and 4.4-fold, respectively, by apigenin
(Fig. 8). Chrysin also remarkably upregulated a and c mRNA
expressions by 5 and 2.9-fold, respectively. A slight increase in
the expressions of the mRNA levels was also detected in ﬂavone-
and 7-hydroxyﬂavone- treated K562 cells. Luteolin and naringenin
had no signiﬁcant effect on the expressions of globin genes.4. Discussion
Epidemiologic studies considerably support the notion that
diets rich in plant ﬂavonoids are associated with a number of ben-
eﬁcial effects that include anti-carcinogenic activities [23–25].
Apigenin’s anti-cancer effect has been well-studied but the deter-
mination of the speciﬁc functional group in its structure that
causes this effect has not yet been done. Here, the effect of apigenin
on erythroid differentiation of K562 cells was determined and the
functional group in its structure responsible for the observed effect
was elucidated.
We have previously reported that apigetrin, a glycoside form of
apigenin, induces HL-60 and K562 cells to differentiate into granu-
locytes and erythrocytes, respectively [11,12]. Considering the
similarity in the chemical structure of apigenin and apigetrin with
glucose at R7 position in apigetrin (Fig. 1), it can be assumed that if
both compounds can induce erythroid differentiation, the glucose
moiety does not have any role in erythroid differentiation induc-
tion. Determination of the expression of glycophorin showed that
Fig. 4. Structural properties of the different ﬂavonoid classes representing the samples used in the experiment. (a) Basic structure and numbering system of ﬂavonoids; (b)
Structural features of the ﬂavone and ﬂavanone in ﬂavonoids: ﬂavone (2-Phenyl-4H-1-benzopyran-4-one), apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-
4-one), 7-hydroxyﬂavone (7-hydroxy-2-phenyl-4H-1-benzopyran-4-one), chrysin (5,7-dihydroxy-2-phenyl-4H-chromen-4-one), luteolin (2-(3,4-dihydroxyphenyl)-5,7-
dihydroxy-4-chromenone) and narigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one). Data represent the means ± SD (n = 3).
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Fig. 5. Erythroid differentiation effect of apigenin and its structural analogs on K562 cells. Cells were treated for 3 days with 25, 50, or 100 lM of apigenin, ﬂavone (2-phenyl-
4H-1-benzopyran-4-one), 7-hydroxyﬂavone (7-hydroxy-2-phenyl-4H-1-benzopyran-4-one), chrysin (5,7-dihydroxy-2-phenyl-4H-chromen-4-one), luteolin (2-(3,4-dihy-
droxyphenyl)-5,7-dihydroxy-4-chromenone) and naringenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one). (a) The anti-proliferation effect of ﬂavonoids on K562
cells assessed by MTT assay; (b) Cell viability of ﬂavonoid-treated cells. After the indicated period of treatment, cells were harvested and suspended in growth medium. Each
cell suspension (10 lL) was mixed with the same volume of 0.4% trypan blue solution and the total number of cells and cell viability (%) were assessed using an automated
cell counter (Cell Countess, Invitrogen) and expressed as percent (%) of control cells. ⁄ Statistically signiﬁcant (P < 0.05) difference between control and treated cells. Data
represent the means ± SD (n = 3).
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Fig. 6. Morphological changes in K562 cells treated with 50 lM apigenin, ﬂavone, 7-hydroxyﬂavone, chrysin, luteolin, or naringenin for 5 days. Cell morphology was observed
using a phase contrast microscope (Leica Microsystems, GmbH); Scale bar represents 10 lm.
Ara-C
Apigenin
DMSO
Chrysin
Flavone 7-hydroxyflavone
Luteolin Naringenin 
Fig. 7. Erythroid differentiation effects of apigenin and its structural analogs on K562 cells. K562 cells were incubated with 50 lM of the different ﬂavonoids for 5 days and
the expression of the erythroid marker glycophorin A was detected using ﬂow cytometry (Guava Express). Ara-C was used as a positive control for erythroid differentiation.
Data represent the means ± SD (n = 3).
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of incubation (Fig. 2a). Apigenin also signiﬁcantly stimulated
hemoglobins a, b, and c production following 8 days of treatment
(Fig. 2b). Results of glycophorin A expression assay as well as the
observed effect on K562 cell morphology (Fig. 3a) revealed similar
differentiation induction abilities of these two compounds (Fig 3b
and c). Treatment with 50 lM apigenin, a lower concentration than
apigetrin (75 lM), had the same level of glycophorin A expression
which is not surprising as it has been proven that glycosylation can
result in a drastic decrease in a ﬂavonoid’s activities [2]. The
absence of glycoside in apigenin’s structure most likely contributed
to its effectiveness at a lower concentration.
The ability of ﬂavones, 7-hydroxyﬂavone, luteolin and chrysin,
and one ﬂavanone, naringenin, to induce erythrocyte differentia-
tion in chronic myeloid leukemia K562 cells was also determined.
Luteolin has been intensively studied during the last decades for itseffect against several cancers such as colon cancer, prostate cancer,
and lung cancer [26–28], and it has been shown that its anticancer
activity was through potentiation of both apoptotic pathways and
suppression of cell survival pathways. The extrinsic apoptosis
pathway is mediated by death receptors (TNFR1/Fas/DR4/DR5),
resulting in sequential activation of initiator caspase 8 and execu-
tor caspases 3 and 7. The intrinsic apoptosis pathway on the other
hand, is initiated by lose of mitochondrial potential [29]. Chrysin
also inhibit the growth of different cancer cells such as cervical
cancer, esophageal squamous carcinoma, breast cancer, malignant
glioma, prostate cancer, and colon cancer by induction of the apop-
totic pathways in leukemia cells in U937 human promonocytic
cells, in megakaryoblastic leukemic cell line MO7e, as well as cause
mitochondrial dysfunction in THP-1 and HL-60 leukemia cells
[30,31]. The anticancer activity of naringenin in different cancer
cell lines as well as in leukemia cell lines U937, THP-1, and K562,
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Fig. 8. Relative expressions of a, b, and c hemoglobin genes in apigenin-treated K562 cells. K562 cells were treated for 3 days with 50 lM of ﬂavonoids after which
hemoglobin mRNA expression levels were determined using real-time PCR. Hemoglobin genes expressions were normalized to the internal control (b-actin) mRNA levels. *
represent statistically signiﬁcant (P < 0.05) means difference between the control and treated cells for a and c hemoglobin genes, respectively. Data represent the means ± SD
(n = 3).
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34]. Based on studies on the therapeutic effect of ﬂavonoids on
cancer, the induction of apoptosis is a common pathway by ﬂavo-
noids to treat cancers, especially hematological cancers [35]. There
are already reports on the differentiation of leukemic cells to spe-
ciﬁc types of blood cells after treatment with dietary ﬂavonoids
[36–38] comparing the different ﬂavonoids’ differentiation-
inducing effect on leukemia cells [13,39,40] but did not identify
the speciﬁc functional group in apigenin’s structure responsible
for the observed differentiation induction effect on K562 cells.
The ﬂavonoids used in this study, except for naringenin, inhibited
K562 cell proliferation in a dose-dependent manner (Fig. 5a). In a
related study using leukocytes, Kanno et al. (2005) reported that
the EC50 of naringenin is 153 ± 15 lM [32]. In this study, the ﬂavo-
noids decreased the growth rate of K562 cells without signiﬁcantly
decreasing the cell viability (80–100%) (Fig. 5b). K562 cells are
multipotential, hematopoietic malignant cells that could differen-
tiate into recognizable progenitors of the erythrocyte, granulocyte,
monocyte, and megakaryocyte lineages. K562 cells treated with
apigenin, chrysin, ﬂavones, and 7-hydroxyﬂavone differentiated
into erythrocytes. In contrast, luteolin and naringenin appeared
to have no erythroid differentiation-inducing effect (Fig. 7). These
results support ﬁndings of studies that demonstrated that apigenin
exerts a broad range of molecular signaling effects in cancer cells,
one of the main target of which is the cell cycle. Apigenin modu-
lates the cell cycle distribution in various malignant cells and
induces the arrest at G2/M and G0/G1 phases by inhibiting the
p34 (cdc2) kinase activity or up-regulating the expression of p21
[41]. In leukemia cells, apigenin block the cell cycle progression
at G2/M phase in HL-60 cells, K562 cells and in human acute lym-
phoblastic leukemia MT-4 cells and at G0/G1 phase in erythroid
TF1 cells [14,15,42,43]. It is believed that cell cycle arrest is a pre-
requisite for hematopoietic cell differentiation, even though the
precise mechanisms between cell cycle and differentiation remain
unclear. Thus, G2/M arrest of K562 cells by apigenin treatment
enabled the cells to undergo erythrocyte differentiation [15].
Another possible explanation for the cytotoxicity of apigenin on
leukemia cell lines is through the induction of autophagy. Ruela-
de-Sousa et al. (2009) showed that a block in cell cycle induces
autophagy in the HL-60 and TF1 cell lines [42]. Inhibition of
autophagy was observed to enhance apoptosis in apigenin-treated
human breast cancer cells [44]. In this study however, the dataobtained clearly showed that apigenin induced cell differentiation
in K562 cells. Microscope observations also ruled out autophagy
(data not shown).
The expressions of fetal hemoglobin components – a-hemoglo-
bin, b-hemoglobin, c-hemoglobin mRNA can validate erythroid
differentiation. Real-time PCR results showed that a and c hemo-
globin expressions were highest in apigenin-treated cells, followed
by the chrysin. As expected, globin genes were not expressed in
signiﬁcant levels in luteolin- and naringenin-treated cells (Fig. 8).
The hemoglobin molecule is a tetramer composed of 2 heterodi-
mers. After the embryonic stages and up to 2 years old in human,
the fetal hemoglobin, is composed of 2 chains of a-globin and 2
chains of c-globin (a2 c2). The adult form of hemoglobin, on the
other hand, is composed of 2 chains of a-globin and 2 chains of
b-globin (a2 b2). Fetal hemoglobin is present in low concentrations
in the mature red blood cells in healthy adults [45]. Our results
showed that apigenin increased the expression of a and c hemo-
globin genes in K562 cells. Increased fetal hemoglobin production
is considered an important alternative for the treatment of
b-thalassemia, a hematological disease caused by mutations in
the b-globin gene. Thus, the synthesis of fetal hemoglobin could
compensate for the shortfall of adult hemoglobin synthesis in
b-thalassemia patients [46]. The c-globin gene is one of the 5 glo-
bin genes located in the b-globin locus, which are respectively, beta
(b)globin gene, delta (d),gamma-A (Ac), gamma-G (Gc), and
epsilon (e)globin.
The ﬂavones apigenin, chrysin, and luteolin, and the ﬂavanone
naringenin have similar structures (Fig. 4), with the unsaturated
C ring between C-2 and C-3 as the main difference between these
two groups of ﬂavonoids. The double bond between C2 and C3 is
essential for higher biological activity such as in antioxidant,
anti-inﬂammatory and anticancer activities [2,17,48,49]. Kawaii
et al. (1999) also highlighted the important role of the C2–C3 dou-
ble bond in monocyte/macrophage differentiation of HL-60 cells by
citrus ﬂavonoids [39]. In another study, apigenin and luteolin, but
not naringenin, induced the granulocytic differentiation of myeloid
leukemia cells [15] and this was attributed to the higher volume/
surface ratio of the molecules of ﬂavones compared to the ﬂava-
nones [2]. Furthermore, C2–C3 double bond contributes to the pla-
nar aspect of the molecule, while its absence makes the phenyl
group (B ring) nearly perpendicular to the rest of the molecule giv-
ing a bigger volume/surface ratio.
276 H. Isoda et al. / Chemico-Biological Interactions 220 (2014) 269–277Additionally, apigenin, chrysin, ﬂavone, 7-hydroxyﬂavone, and
luteolin are structurally different ﬂavones owing to the number
and the position of the hydroxyl groups in their structures, with
luteolin having the highest number of hydroxyl groups, followed
by apigenin, chrysin, 7-hydroxyﬂavone and ﬁnally ﬂavone, which
does not have any hydroxyl in its chemical structure (Fig. 4). The
number of hydroxyl group (–OH) and their position in the ﬂavo-
noid’s skeleton are two of the contributing factors for their bioac-
tivities [19]. For instance, more hydroxyl groups lead to better
ROS-scavenging and anti-cancer activity [50], and the most active
compounds are those having hydroxyl groups at C40 and/or C30
[47]. Wang et al. (2012) indicate that pro-anthocyanidins from
antioxidant grape seeds are likely to induce monocytic differentia-
tion in K562 cells, mostly through decreasing iROS formation and
inducing phase G1 arrest [51]. In this study, results indicate that
apigenin had greater erythroid differentiation effect on K562 cells
than chrysin that lacks the 40-OH groups). We suggest that the
anti-oxidant activity of apigenin is due to the free hydroxyl group
at the C-40 position that enhanced its erythroid differentiation abil-
ity. On the other hand, luteolin (with 3040-OH groups) was appar-
ently still not as effective as differentiation inducer compared to
apigenin. Matsuo et al. (2005), studied the cytotoxicity (LD50) of
nine ﬂavonoids toward two types of normal human cells [52]
and found that luteolin was the most toxic toward human umbil-
ical vein endothelial cells compared to other ﬂavonoids even
though ﬂavonoids cytotoxicity has been shown to be dependent
on the cell type. Here, the MTT and cell viability assay results
showed that among the six ﬂavonoids, luteolin-treated K652 cells
had the lowest cell proliferation rate (Fig. 5a), and did not undergo
cell differentiation based on the glycophorin A and the hemoglobin
genes expressions (Figs. 7 and 8).
5. Conclusions
Here, we have shown that the ﬂavonoids representing the func-
tional groups in the apigenin structure had differentiation–induc-
tion effect on K562 cells. The effectiveness of these ﬂavonoids in
the induction of erythroid cell differentiation, based on glycopho-
rin A and hemoglobin genes expressions, may be ranked as: apige-
nin > chrysin > ﬂavone/7-hydroxyﬂavone > luteolin/naringenin.
These results suggest that the strong erythroid differentiation
effect of apigenin on K562 cells was due to the presence of C2–
C3 double bond and the hydroxyl groups. The hydroxyl groups
most likely rendered apigenin effective for inducing cell differenti-
ation but also probably made the other ﬂavonoids cytotoxic as in
the case of luteolin. This study provided the data for the relation-
ship between the ﬂavonoids structure and their cell differentiation
induction effect and provides new information for the design of
cancer chemopreventive agents for human leukemia.
Conﬂict of Interest
The authors declare that there are no conﬂicts of interest.
Transparency Document
The Transparency document associated with this article can be
found in the online version.Acknowledgment
This research was partially supported by the JST-JICA SATREPS
of Japan.References
[1] S. Chandra, K. Sah, A. Bagewadi, V. Keluskar, A. Shetty, R. Ammanagi, Z. Naik,
Additive and synergiatic effect of phytochemicals in prevention of oral cancer,
Eur. J. Gen. Dent. 1 (2012) 142–147.
[2] A. Kale, S. Gawande, S. Kotwal, Cancer phytotherapeutics: role for ﬂavonoids at
the cellular level, Phytotherapy Res. 22 (2008) 567–577.
[3] M.K. Chahar, N. Sharma, M.P. Dobhal, Y.C. Joshi, Flavonoids: a versatile source
of anticancer drugs, Pharmacognosy Rev. 5 (2011) 1–12.
[4] W. Ren, Z. Qiao, H. Wang, L. Zhu, L. Zhang, Flavonoids: promising anticancer
agents, Med. Res. Rev. 23 (2003) 519–534.
[5] P.C. Hollman, I.C.W. Arts, Flavonoils, ﬂavones and ﬂavonols-nature, occurrence
and dietary burden, J. Sci. Food Agric. 80 (2000) 1081–1093.
[6] X. Tong, R.T. Van Dross, A. Abu-Yousif, A.R. Morrison, J.C. Pelling, Apigenin
prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA
stabilization and translational inhibition, Mol. Cell. Biol. 27 (2007) 283–296.
[7] J.H. Lee, H.Y. Zhou, S.Y. Cho, Y.S. Kim, Y.S. Lee, C.S. Jeong, Anti-inﬂammatory
mechanisms of apigenin: inhibition of cyclooxygenase-2 expression, adhesion
of monocytes to human umbilical vein endothelial cells, and expression of
cellular adhesion molecules, Arch. Pharm. Res. 30 (2007) 1318–1327.
[8] N. Begum, N.R. Prasad, K. Thayalan, Apigenin protects gamma-radiation
induced oxidative stress, hematological changes and animal survival in
whole body irradiated Swiss albino mice, Int. J. Nutr. Pharmacol. Neurol. Dis.
2 (2012) 45–52.
[9] F. Yin, A.E. Giuliano, R.E. Law, A.J. Van Herle, Apigenin inhibits growth and
induces G2/M arrest by modulating cyclin-cdk regulators and ERK MAP kinase
activation in breast carcinoma cells, Anticancer Res. 21 (2001) 413–420.
[10] W. Wang, L. Heideman, C.S. Chung, J.C. Pelling, K.J. Koehler, D.F. Birt, Cell-cycle
arrest at G2/M and growth inhibition by apigenin in human colon carcinoma
cell lines, Mol. Carcinog. 28 (2000) 102–110.
[11] S. Caltagirone, C. Rossi, A. Poggi, F.O. Ranelletti, P.G. Natali, M. Brunetti, F.B.
Aiello, M. Piantelli, Flavonoids apigenin and quercetin inhibit melanoma
growth and metastatic potential, Int. J. Cancer 87 (2000) 595–600.
[12] F. Yin, A.E. Giuliano, A.J. Van Herle, Growth inhibitory effects of ﬂavonoids in
human thyroid cancer cell lines, Thyroid 9 (1999) 369–376.
[13] T. Takahashi, M. Kobori, H. Shinmoto, T. Tsushida, Structure-activity
relationships of ﬂavonoids and the induction of granulocyticor monocytic-
differentiation in HL60 human myeloid leukemia cells, Biosci. Biotechnol.
Biochem. 62 (1998) 2199–2204.
[14] E. Nakazaki, S. Tsolmon, J. Han, H. Isoda, Proteomic study of granulocytic
differentiation induced by apigenin 7-glucoside in human promyelocytic
leukemia HL-60 cells, Eur. J. Nutr. 52 (2013) 25–35.
[15] S. Tsolmon, E. Nakazaki, J. Han, H. Isoda, Apigetrin induces erythroid different
of human leukemia cells K562: proteomics approach, Mol. Nutr. Food Res. 55
(2011) 93–102.
[16] M. Leszczyniecka, T. Roberts, P. Dent, S. Grant, P.B. Fisher, Differentiation
therapy of human cancer: basic science and clinical applications, Pharmacol.
Ther. 90 (2001) 105–156.
[17] G. Moghaddam, S.A. Ebrahimi, N. Rahbar-Roshandel, A. Foroumadi,
Antiproliferative activity of ﬂavonoids: inﬂuence of the sequential
methoxylation state of the ﬂavonoid structure, Phytother. Res. 26 (2012)
1023–1028.
[18] S. Kilani-Jaziri, V. Frachet, W. Bhouri, K. Ghedira, L. Chekir-Ghedira, X. Ronot,
Flavones inhibit the proliferation of human tumor cancer cell lines by inducing
apoptosis, Drug. Chem. Toxicol. 35 (2012) 1–10.
[19] A. Pick, H. Müller, R. Mayer, B. Haenisch, I.K. Pajeva, M. Weigt, H. Bönisch, C.E.
Müller, M. Wiese, Structure-activity relationships of ﬂavonoids as inhibitors of
breast cancer resistance protein (BCRP), Bioorg. Med. Chem. 19 (2011) 2090–
2102.
[20] S.B. Lotito, B. Frei, Dietary ﬂavonoids attenuate tumor necrosis factor a
induced adhesion molecule expression in human aortic endothelial cells.
Structure-function relationships and activity after ﬁrst pass metabolism, J.
Biol. Chem. 281 (2006) 102–110.
[21] http://www.kisnet.or.jp/nappa/software/star/.
[22] D.K. Morrison, The 14-3-3 proteins: integrators of diverse signaling cues that
impact cell fate and cancer development, Trends Cell. Biol. 19 (2008) 16–23.
[23] K.A. Steinmetz, J.D. Potter, Vegetables, fruit, and cancer prevention: a review, J.
Am. Diet. Assoc. 96 (1996) 1027–1039.
[24] L.O. Dragsted, M. Strube, J.C. Larsen, Cancer-protective factors in fruits and
vegetables: biochemical and biological background, Pharmacol. Toxicol. 72
(1993) 116–135.
[25] G. Block, Micronutrients and cancer: time for action?, J Natl. Cancer Inst. 2
(1993) 846–848.
[26] D.Y. Lim, H.J. Cho, J. Kim, C.W. Nho, K.W. Lee, J.H. Park, Luteolin decreases IGF-II
production and downregulates insulin-like growth factor-I receptor signaling
in HT-29 human colon cancer cells, BMC Gastroenterol. 12 (2012), http://
dx.doi.org/10.1186/1471-230X-12-9.
[27] J. Fang, Q. Zhou, X.L. Shi, B.H. Jiang, Luteolin inhibits insulin-like growth factor
1 receptor signaling in prostate cancer cells, Carcinogenesis 28 (2006) 713–
723.
[28] J.H. Kim, E.O. Lee, H.J. Lee, J.S. Ku, M.H. Lee, D.C. Yang, S.H. Kim, Caspase
activation and extracellular signal-regulated kinase/Akt inhibition were
involved in luteolin-induced apoptosis in Lewis lung carcinoma cells, Ann. N.
Y. Acad. Sci. 1095 (2007) 598–611.
H. Isoda et al. / Chemico-Biological Interactions 220 (2014) 269–277 277[29] Y. Lin, R. Shi, X. Wang, H.M. Shen, Luteolin, a ﬂavonoid with potentials
for cancer prevention and therapy, Curr. Cancer Drug Targets 8 (2008)
634–646.
[30] B.Y. Khoo, S.L. Chua, P. Balaram, Apoptotic effects of chrysin in human cancer
cell lines, Int. J. Mol. Sci. 11 (2010) 2188–2199.
[31] X. Li, J.N. Wang, J.M. Huang, X.K. Xiong, M.F. Chen, C.N. Ong, H.M. Shen, X.F.
Yang, Chrysin promotes tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) induced apoptosis in human cancer cell lines,
Toxicol. In Vitro 25 (2011) 630–635.
[32] S. Kanno, A. Tomizawa, T. Hiura, Y. Osanai, A. Shouji, M. Ujibe, T. Ohtake, K.
Kimura, M. Ishikawa, Inhibitory effects of naringenin on tumor growth in
human cancer cell lines and sarcoma S-180-implanted mice, Biol. Pharm. Bull.
28 (2005) 527–530.
[33] C.Y. Jin, C. Park, J.H. Lee, K.T. Chung, T.K. Kwon, G.Y. Kim, B.T. Choi, Y.H. Choi,
Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small
molecule Bcl-2 inhibitor, HA 14–1, in human leukemia U937 cells, Toxicol. In
Vitro 23 (2009) 259–265.
[34] J.H. Park, C.Y. Jin, B.K. Lee, G.Y. Kim, Y.H. Choi, Y.K. Jeong, Naringenin induces
apoptosis through downregulation of Akt and caspase-3 activation in human
leukemiaTHP-1cells, Food Chem. Toxicol. 46 (2008) 3684–3690.
[35] I.M. Ghobrial, T.E. Witzig, A.A. Adjei, Targeting apoptosis pathways in cancer
therapy, CA Cancer J. Clin. 55 (2005) 178–194.
[36] W.W. Huang, J.S. Yang, C.F. Lin, W.J. Ho, M.R. Lee, Pycnogenol induces
differentiation and apoptosis in human promyeloid leukemia HL-60 cells,
Leuk. Res. 29 (2005) 685–692.
[37] A. Constantinou, K. Kiguchi, E. Huberman, Induction of differentiation and DNA
strand breakage in human HL-60 and K-562 leukemia cells by genistein,
Cancer Res. 50 (1990) 2618–2624.
[38] S.Y. Kim, J.J. Gao, H.K. Kang, Two ﬂavonoids from the leaves of Morus alba
induce differentiation of the human promyelocytic leukemia (HL-60) cell line,
Biol. Pharm. Bull. 23 (2000) 451–455.
[39] S. Kawaii, Y. Tomono, E. Katase, K. Ogawa, M. Yano, Effect of citrusﬂavonoidson
HL-60cell differentiation, Anticancer Res. 19 (1999) 1261–1269.
[40] Y. Jing, S. Waxman, Structural requirements for differentiation-induction and
growth-inhibition of mouse erythroleukemia cells by isoﬂavones, Anticancer
Res. 15 (1995) 1147–1152.[41] S. Shukla, S. Gupta, Apigenin: a promising molecule for cancer prevention,
Pharm. Res. 27 (2010) 962–978.
[42] R.R. Ruela-de-Sousa, G.M. Fuhler, N. Blom, C.V. Ferreira, H. Aoyama, M.P.
Peppelenbosch, Cytotoxicity of apigenin on leukemia cell lines: implications
for prevention and therapy, Cell. Death Dis. 1 (e19) (2010) 2009, http://
dx.doi.org/10.1038/cddis.18.
[43] O.O. Fil’chenkov, M.P. Zavelevych, Comparative effects of ﬂavonoids on cell
cycle passage and apoptosis induction in human acute lymphoblastic
leukemia MT-4 cells, Ukr. Biokhim. Zh. 81 (2009) 33–39.
[44] X. Cao, B. Liu, W. Cao, W. Zhang, F. Zhang, H. Zhao, R. Meng, L. Zhang, R. Niu, X.
Hao, B. Zhang, Autophagy inhibition enhances apigenin-induced apoptosis in
human breast cancer cells, Chin. J. Cancer Res. 25 (2013) 212–222.
[45] A. Wilber, A.W. Nienhuis, D.A. Persons, Transcriptional regulation of fetal to
adult hemoglobin switching: new therapeutic opportunities, Blood 117 (2010)
3945–3953.
[46] N.F. Olivieri, D.J. Weatherall, The therapeutic reactivation of fetal haemoglobin,
Hum. Mol. Genet. 7 (1998) 1655–1658.
[47] B. Modak, M.L. Contreras, F. González-Nilo, R. Torres, Structure–antioxidant
activity relationships of ﬂavonoids isolated from the resinous exudate of
Heliotropium sinuatum, Bioorg. Med. Chem. Lett. 15 (2005) 309–312.
[48] M. Comalada, I. Ballester, E. Bailón, S. Sierra, J. Xaus, J. Gálvez, F.S. de Medina, A.
Zarzuelo, Inhibition of pro-inﬂammatory markers in primary bone marrow-
derived mouse macrophages by naturally occurring ﬂavonoids: analysis of the
structure-activity relationship, Biochem. Pharmacol. 72 (2006) 1010–1021.
[49] Y.S. Touil, A. Fellous, D. Scherman, G.G. Chabot, Flavonoid-induced
morphological modiﬁcations of endothelial cells through microtubule
stabilization, Nutr. Cancer 61 (2009) 310–321.
[50] H. Chang, M. Mi, W. Ling, J. Zhu, Q. Zhang, N. Wei, Y. Zhou, Y. Tang, X. Yu, T.
Zhang, J. Wang, J. Yuan, Structurally related anticancer activity of ﬂavonoids:
involvement of reactive oxygen species generation, J. Food Biochem. 34 (2010)
1–14.
[51] M. Wang, L. Wang, X.J. Pan, H. Zhang, Monocytic differentiation of K562 cells
induced by proanthocyanidins from grape seeds, Arch. Pharm. Res. 35 (2012)
129–135.
[52] M. Matsuo, N. Sasaki, K. Saga, T. Kaneko, Cytotoxicity of ﬂavonoids toward
cultured normal human cells, Biol. Pharm. Bull. 28 (2005) 253–259.
